Home > Publications Database > Diffusion tensor imaging of sequential neuropathological patterns in progressive supranuclear palsy. > print

001     279368
005     20250713001459.0
024 7 _ |a 10.3389/fnagi.2025.1569302
|2 doi
024 7 _ |a pmid:40547840
|2 pmid
024 7 _ |a pmc:PMC12179216
|2 pmc
024 7 _ |a altmetric:178470671
|2 altmetric
037 _ _ |a DZNE-2025-00745
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Barlescu, Lavinia
|0 P:(DE-2719)9002368
|b 0
|u dzne
245 _ _ |a Diffusion tensor imaging of sequential neuropathological patterns in progressive supranuclear palsy.
260 _ _ |a Lausanne
|c 2025
|b Frontiers Research Foundation
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1751975661_27241
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a A neuropathological cerebral staging concept for progressive supranuclear palsy (PSP) has been proposed that tau inclusions in PSP may progress in a sequential regional pattern. The objective was to develop a hypothesis-guided region/tract of interest-based (ROI/TOI) approach to use diffusion tensor imaging (DTI) targeted to analyze in vivo the regions that are prone to be involved at each neuropathological stage of PSP.Two data cohorts were analyzed: cohort A of 78 PSP patients [55 Richardson's syndrome (PSP-RS) and 23 PSP with predominant parkinsonism (PSP-P)] and 63 controls, recorded at 3.0T at multiple sites, and a single-site cohort B constituted by 1.5T data of 66 PSP patients (46 PSP-RS and 20 PSP-P) and 44 controls. In cohort A, 21 PSP patients (13 PSP-RS and 8 PSP-P) and 17 controls obtained a follow-up scan after 17 months. Whole brain-based spatial statistics (WBSS) was used to identify the alterations in PSP patients vs. controls. The combined ROI- and TOI-based approach targeted structures that are prone to be involved during the course of PSP.WBSS demonstrated alterations predominantly in brainstem/midbrain, basal ganglia, and frontal lobe, more pronounced in the longitudinal data. Statistical analyses of the ROIs/TOIs showed a sequential pattern of structures that were assigned to previously defined neuropathological steps.The combined ROI- and TOI-based DTI approach was able to map the disease stages of PSP in vivo cross-sectionally and longitudinally, lending support to DTI as a technical marker for imaging disease progression according to PSP stages. This approach might be useful as a tool for stratification of PSP patients MRI with respect to its proposed neuropathological progression in future longitudinal and autopsy-controlled studies.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a diffusion tensor imaging (DTI)
|2 Other
650 _ 7 |a neuropathology
|2 Other
650 _ 7 |a progressive supranuclear palsy
|2 Other
650 _ 7 |a sequential pattern
|2 Other
650 _ 7 |a tau protein
|2 Other
693 _ _ |0 EXP:(DE-2719)DESCRIBE-PSP-20160101
|5 EXP:(DE-2719)DESCRIBE-PSP-20160101
|e DZNE Clinical Registry Study of Neurodegenerative Diseases in Patients with Progressive Supranuclear Paresis (PSP)
|x 0
700 1 _ |a Höglinger, Günter U
|0 P:(DE-2719)2811373
|b 1
|u dzne
700 1 _ |a Volkmann, Heiko
|b 2
700 1 _ |a Ludolph, Albert C
|0 P:(DE-2719)2812633
|b 3
|u dzne
700 1 _ |a Del Tredici, Kelly
|b 4
700 1 _ |a Braak, Heiko
|b 5
700 1 _ |a Müller, Hans-Peter
|b 6
700 1 _ |a Kassubek, Jan
|0 P:(DE-2719)9001967
|b 7
|u dzne
700 1 _ |a Group, DESCRIBE-PSP Study
|b 8
|e Collaboration Author
700 1 _ |a Brandt, Moritz
|0 P:(DE-2719)2812107
|b 9
|e Contributor
|u dzne
700 1 _ |a Bürger, Katharina
|0 P:(DE-2719)2811351
|b 10
|e Contributor
|u dzne
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 11
|e Contributor
|u dzne
700 1 _ |a Falkenburger, Björn
|0 P:(DE-2719)2814178
|b 12
|e Contributor
|u dzne
700 1 _ |a Flöel, Agnes
|0 P:(DE-2719)2812683
|b 13
|e Contributor
|u dzne
700 1 _ |a Glanz, Wenzel
|0 P:(DE-2719)2811614
|b 14
|e Contributor
|u dzne
700 1 _ |a Höglinger, Günter
|0 P:(DE-2719)2811373
|b 15
|e Contributor
|u dzne
700 1 _ |a Janowitz, Daniel
|0 P:(DE-2719)9002557
|b 16
|e Contributor
|u dzne
700 1 _ |a Katzdobler, Sabrina
|0 P:(DE-2719)9001160
|b 17
|e Contributor
|u dzne
700 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 18
|e Contributor
|u dzne
700 1 _ |a Kimmich, Okka
|0 P:(DE-2719)9002382
|b 19
|e Contributor
|u dzne
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 20
|e Contributor
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 21
|e Contributor
|u dzne
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 22
|e Contributor
|u dzne
700 1 _ |a Prudlo, Johannes
|0 P:(DE-2719)2380559
|b 23
|e Contributor
|u dzne
700 1 _ |a Schneider, Luisa-Sophie
|0 P:(DE-2719)9002878
|b 24
|e Contributor
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 25
|e Contributor
|u dzne
700 1 _ |a Spruth, Eike Jakob
|0 P:(DE-2719)2812446
|b 26
|e Contributor
700 1 _ |a Synofzik, Matthis
|0 P:(DE-2719)2811275
|b 27
|e Contributor
|u dzne
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 28
|e Contributor
|u dzne
700 1 _ |a Wilke, Carlo
|0 P:(DE-2719)2814101
|b 29
|e Contributor
|u dzne
773 _ _ |a 10.3389/fnagi.2025.1569302
|g Vol. 17, p. 1569302
|0 PERI:(DE-600)2558898-9
|p 1569302
|t Frontiers in aging neuroscience
|v 17
|y 2025
|x 1663-4365
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/279368/files/DZNE-2025-00745.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/279368/files/DZNE-2025-00745.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:279368
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 0
|6 P:(DE-2719)9002368
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2811373
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2812633
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 7
|6 P:(DE-2719)9001967
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 9
|6 P:(DE-2719)2812107
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 10
|6 P:(DE-2719)2811351
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 11
|6 P:(DE-2719)2000005
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 12
|6 P:(DE-2719)2814178
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 13
|6 P:(DE-2719)2812683
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 14
|6 P:(DE-2719)2811614
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 15
|6 P:(DE-2719)2811373
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 16
|6 P:(DE-2719)9002557
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 17
|6 P:(DE-2719)9001160
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 18
|6 P:(DE-2719)2810394
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 19
|6 P:(DE-2719)9002382
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 20
|6 P:(DE-2719)2811659
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 21
|6 P:(DE-2719)2811024
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 22
|6 P:(DE-2719)2811122
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 23
|6 P:(DE-2719)2380559
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 24
|6 P:(DE-2719)9002878
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 25
|6 P:(DE-2719)2811324
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 27
|6 P:(DE-2719)2811275
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 28
|6 P:(DE-2719)2000026
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 29
|6 P:(DE-2719)2814101
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-16
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT AGING NEUROSCI : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-01-06T07:55:22Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-01-06T07:55:22Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-16
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-01-06T07:55:22Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center (Ulm)
|l Clinical Study Center (Ulm)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)5000077
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21